COVID-19 plus flu test allows patients to collect sample at home

Dec 07, 2020 - 03:13 PM
FDA product update

The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to collect a sample at home and ship it to a laboratory for analysis.

The Quest Diagnostics test received emergency use authorization for use by individuals with a suspected respiratory viral infection consistent with COVID-19 when their health care provider deems home collection appropriate.

“With just one swab or sample, combination tests that are authorized for use with home-collected samples can be used to get answers to Americans faster, in the comfort and relative safety of their home, which allows patients to continue to quarantine while awaiting results,” said FDA Commissioner Stephen Hahn, M.D.

Related News Articles

Headline
CMS Administrator Oz and Deputy Administrator Brillman discuss agency’s focus on innovation, reducing waste
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
CDC releases report on flu, COVID-19 vaccination coverage for health care workers for 2024-25 respiratory season 
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
Study estimates more than 155,000 uncounted COVID-19 deaths occurred early during pandemic 
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
Current flu vaccine found to be 30% effective in reducing adult hospitalizations, 41% for children 
The Centers for Disease Control and Prevention released a report March 12 on the effectiveness of the flu vaccine for the 2025-2026 flu season, finding that it…
Headline
CDC report highlights low use of COVID-19 antivirals among people 65 and older 
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
FDA issues guidance on wellness products, clinical decision support software
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…